Fundraising FoxVeltro Argento — Full Portfolio
3 tracked investments · listed companies and verified rows first
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
Jay Caplan(Founder)inHarith Rajagopalan(Co-Founder and CEO)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
BoardAllan Will(Director)inNimesh Shah(Director)in
Board seatMarc Elia· per SEC Form D · $100M raise · filed Jun 2021
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPGeneral CatalystMithril Capital ManagementDomain Associates+1 more
.png)
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)inRebecca Dabora(Executive Officer)in
Board seatMarc Elia· per SEC Form D · $23.7M raise · filed Nov 2022
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
BiotechWatertown, US
Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Armon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)
Board seatMarc Elia· per SEC Form D · $70.2M raise · filed Jun 2020
Co-investorsAlumni Ventures+ND CapitalGV (Google Ventures)Illumina VenturesInvusJDRF T1D Fund+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.